Pliant Therapeutics reported a net loss of $0.38 per share for the fourth quarter of 2025, beating the consensus analyst estimate of a $0.44 loss by $0.06. The upside was driven by disciplined cost management, with research and development expenses falling to $15.6 million from $17.9 million and general and administrative costs dropping to $8.0 million from $10.3 million, largely due to the discontinuation of the BEACON‑IPF program and a 45% workforce reduction in May 2025.
The company’s net loss for the quarter was $23.6 million, a significant improvement from the $57.8 million loss reported in the same period a year earlier. The reduction in operating expenses, combined with the elimination of the BEACON‑IPF trial, underpins the stronger profitability profile. Cash, cash equivalents and short‑term investments stood at $192.4 million as of December 31 2025, down from $243.3 million at September 30 2025, but still sufficient to fund operations through the second half of 2028.
Management highlighted the progress of its lead oncology candidate, PLN‑101095, noting that positive Phase 1 data have accelerated the development plan and prompted the initiation of a Phase 1b indication‑expansion trial. The company’s strategic pivot away from fibrotic disease toward oncology reflects a focus on high‑potential markets and a clearer path to commercial viability.
Investors reacted cautiously, citing the company’s reduced cash balance and the CEO’s sale of a significant portion of his stake. Analysts maintained a “Reduce” rating, reflecting a conservative view of the company’s near‑term prospects despite the earnings beat.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.